Literature DB >> 25768993

Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas: the SEXIE-R-CHOP-14 trial of the DSHNHL.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25768993

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


× No keyword cloud information.
  6 in total

1.  Rituximab maintenance therapy in diffuse large B-cell lymphoma: is XY the most important variable?

Authors:  Matthew A Lunning; James O Armitage
Journal:  Haematologica       Date:  2015-07       Impact factor: 9.941

2.  Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma.

Authors:  Shama Jaswal; Vanessa Sanders; Priyanka Pullarkat; Stephanie Teja; Amber Salter; Marcus P Watkins; Norman Atagu; Daniel R Ludwig; Joyce Mhlanga; Vincent M Mellnick; Linda R Peterson; Nancy L Bartlett; Brad S Kahl; Todd A Fehniger; Armin Ghobadi; Amanda F Cashen; Neha Mehta-Shah; Joseph E Ippolito
Journal:  Cancers (Basel)       Date:  2022-06-14       Impact factor: 6.575

3.  Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States.

Authors:  Chadi Nabhan; Xiaolei Zhou; Bann-Mo Day; Keith Dawson; Andrew D Zelenetz; Jonathan W Friedberg; James R Cerhan; Brian K Link; Christopher R Flowers
Journal:  Am J Hematol       Date:  2016-05-24       Impact factor: 10.047

4.  Does gender matter in non-hodgkin lymphoma? Differences in epidemiology, clinical behavior, and therapy.

Authors:  Nurit Horesh; Netanel A Horowitz
Journal:  Rambam Maimonides Med J       Date:  2014-10-29

Review 5.  Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update.

Authors:  Jung Yong Hong; Cheolwon Suh; Won Seog Kim
Journal:  F1000Res       Date:  2016-08-08

6.  Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy.

Authors:  Candice Jamois; Ekaterina Gibiansky; Leonid Gibiansky; Vincent Buchheit; Denis Sahin; Guillaume Cartron; Robert Marcus; Wolfgang Hiddemann; John F Seymour; Jonathan C Strefford; Chantal E Hargreaves; Georgina Meneses-Lorente; Nicolas Frey; Günter Fingerle-Rowson
Journal:  Br J Clin Pharmacol       Date:  2019-05-17       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.